TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01961154
Drug: Asthma medication reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
Study: NCT01265576
Drug: VT-122 (propranolol plus etodolac)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)\[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID\]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
Study: NCT01265576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
Study: NCT00915876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Paricalcitol 1 mcg QD x 8 weeks
Study: NCT02591901
Drug: Uro vaxom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prevention of recurrent symptomatic lower urinary tract infections
Study: NCT02355184
Drug: PRO 140 350mg weekly SQ injection.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCR5 Antagonist
Study: NCT02589457
Drug: Viread® tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate 1T PO
Study: NCT03122561
Drug: Paracetamol 500 mg tablet at morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral paracetamol will be administered at 8.00 am
Study: NCT03122561
Drug: Paracetamol 500 mg tablet at night
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral paracetamol will be administered at 8.00 pm
Study: NCT01763580
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT03774524
Drug: placebo to TA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 ml saline iv
Study: NCT00071721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
Study: NCT00791843
Drug: Growth hormone releasing hormone/ placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
Study: NCT00052936
Drug: CHOP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00052936
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00052936
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01937013
Drug: Saline Nasal Mist
Normalized name: Saline Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive placebo on either study visit 2 or 3.
Study: NCT03118492
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00068393
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
Study: NCT00915408
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
Study: NCT04068272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound
Study: NCT00679029
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00679029
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03018067
Drug: RDX227675
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04571437
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine metronomic combined with Letrozole
Study: NCT01404338
Drug: Placebo Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01167738
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/mq days 1-28 every 4 weeks
Study: NCT02469688
Drug: ASP4070
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular or intradermal
Study: NCT02469688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular or intradermal
Study: NCT01736397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02993328
Drug: SAN021 Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study: NCT03652571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01604928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04284397
Drug: Low dose ASA
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sub-group of older adults will be re-tested after 7 days of treatment with low-dose aspirin.
Study: NCT04392375
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the time of enrollment, patients will be randomized to either the study drug (oral Nifedipine XL 30mg) or identical placebo.
Study: NCT00054938
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00054938
Drug: Vitamins: B6, B12, and folate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02161146
Drug: AGN-229666
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop of AGN-229666 in the eye on Days 1 and 15.
Study: NCT04566003
Drug: [18F]PI-2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]PI-2620 radiotracer.
Study: NCT04566003
Drug: [18F]MK-6240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a bolus IV of approximately 5mCi of \[18F\]MK-6240 radiotracer.
Study: NCT03709849
Drug: experimental group: Bushen Culuan Decoction and Clomiphene Citrate Tablets placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same as group description including dosage, frequency and duration
Study: NCT03709849
Drug: control group: Clomiphene Citrate Tablets and Bushen Culuan Decoction placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the same as group description including dosage, frequency and duration
Study: NCT03092765
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT03092765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT02362672
Drug: NKTR-181 BID tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-181 tablets 100-400 mg twice daily (BID)
Study: NCT02497040
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: local injection
Study: NCT02954692
Drug: thiazolidinediones
Normalized name: Thiazolidinediones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02954692
Drug: alpha-glucosidase inhibitors
Normalized name: alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01502813
Drug: Citicoline, Omega-3 Fatty Acids and Creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
Study: NCT02954692
Drug: GLP1 Receptor Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: pen for injection~Route of administration: subcutaneous
Study: NCT02954692
Drug: Dipeptidyl peptidase-IV (DPP-IV) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02241083
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02241083
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01253551
Drug: Treatment sequence AB
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Study: NCT01253551
Drug: Treatment sequence BA
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Study: NCT02448537
Drug: PM01183
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01946022
Drug: randomization between the two GnRH analogues (agonist and antagonist)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02448537
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02593526
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic
Study: NCT01584180
Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
Study: NCT03638999
Drug: Ketorolac Trometamol 30Mg/1mL Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the intervention group will receive intravenous injection of 1 ml of Ketorlac 30 mg/ml prior to the start of the ureteroscopic procedure.
Study: NCT03638999
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the control group will receive 1 ml of 0.9% injectable normal saline prior to the start of the ureteroscopic procedure.
Study: NCT01542723
Drug: LMWH
Normalized name: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Study: NCT02175394
Drug: Microgynon®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01669174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01669174
Drug: BYM338
Approvals — FDA: no, EMA: no, PMDA: no
Description: BYM338
Study: NCT01560325
Drug: CKD-516 inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-516: 3.3\~13mg/m2/day
Study: NCT00757458
Drug: EDTA without re-filling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
Study: NCT00911612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert capsule matching the study drug, given twice daily
Study: NCT00497289
Drug: Lipofundin MCT/LCT 20 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily i.v. infusion for up to 5 days
Study: NCT00497289
Drug: Lipidem 20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily i.v. infusion for up to 5 days
Study: NCT03973411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacients will receibe standard spinal anesthesia
Study: NCT00708214
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 at high and medium dosages
Study: NCT02041117
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
Study: NCT01073904
Drug: Postinor 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 1.5 mg tablet
Study: NCT01480947
Drug: Bio-three
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
Study: NCT02579564
Drug: Oncorine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04069325
Drug: simiaowan
Approvals — FDA: no, EMA: no, PMDA: no
Description: pills, 6g twice daily (BID), oral, 12 weeks
Study: NCT04069325
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pills, 6g twice daily (BID), oral, 12 weeks
Study: NCT01250873
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: po administration
Study: NCT04594369
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib-matching oral tablet.
Study: NCT01214083
Drug: N-acetylcysteine + high-dose naltrexone (150 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be evaluated weekly for 12 weeks.
Study: NCT03181802
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
Study: NCT00194688
Drug: H. pylori treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03406819
Drug: Heparinized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary infusion 2ml for single time
Study: NCT00169000
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID
Study: NCT01728519
Drug: AllerT SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
Study: NCT01728519
Drug: AllerT ID
Approvals — FDA: no, EMA: no, PMDA: no
Description: AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
Study: NCT01728519
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
Study: NCT02949843
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive other treatment
Study: NCT02949843
Drug: Tyrosine Kinase Inhibitor
Normalized name: Protein-tyrosine kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02524743
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
Study: NCT01307800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03633305
Drug: Hypnotics
Normalized name: HYPNOTICS AND SEDATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication used 1 to 7 nights/week for 6 to 8 weeks.
Study: NCT01490879
Drug: Nexagon® Low Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
Study: NCT01490879
Drug: Nexagon® Medium Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
Study: NCT01490879
Drug: Nexagon® High Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
Study: NCT01490879
Drug: Nexagon® vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
Study: NCT00650325
Drug: Zoloft® Tablets 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fasting
Study: NCT00147667
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01303406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00347477
Drug: HyperHAES vs. RA-solution/NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02189304
Drug: Symbicort Turbohaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort Turbohaler taken as 2 inhalations
Study: NCT03500783
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during coronary artery bypass grafting.
Study: NCT04172259
Drug: Doxorubicin liposome
Normalized name: Doxorubicin liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD
Study: NCT04172259
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CTX
Study: NCT01225081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT03075878
Drug: ALXN1830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via IV infusion.
Study: NCT02118727
Drug: Placebo (for Memantine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All randomized patients will be instructed to take one tablet once a day for the first two weeks from a blinded bottle that contains 10 mg tablets or matching placebo. At week three, patients will be instructed to take one tablet twice a day from the 10 mg bottle or matching placebo. At week five, patients will be instructed to take one tablet in the morning and two tablets in the evening from the 10 mg bottle or matching placebo. At week seven patients will be instructed to take two tablets twice a day from the 10 mg bottle or matching placebo.
Study: NCT00577980
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
Study: NCT00449137
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
Study: NCT00449137
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
Study: NCT03804229
Drug: Placebo soft capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 subjects are randomly divided into two groups by 1:1. About 350 patients in the active group take two pills of placebo soft capsule each time, three times a day, 0.5 hours before meal, taking with lukewarm water.
Study: NCT04224415
Drug: C225+CPT-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Systemic C225+CPT-11 every 14 days:~C225 500 mg/m2 IV over 90 minutes on Day 1; Irinotecan 180 mg/m2 IV on Day 1
Study: NCT04053699
Drug: Von Willebrand Factor-Containing Product
Normalized name: von Willebrand factor-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active substances: VWF concentrates, VWF/FVIII concentrates, Cryoprecipitate VWF-containing products licensed in each participating country
Study: NCT01328145
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg /day
Study: NCT02586610
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
Study: NCT01527695
Drug: ER tablet 100 mg AZD3241
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days
Study: NCT01527695
Drug: Placebo for AZD3241 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-6 tablets twice daily from Day 2 until Day 56±3 days